David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky ...

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, but its stock sank more than 11% in trading despite the win.

Eli Lilly stock trades above all major moving averages, indicating a strongly bullish technical trend. Analysts see 3% upside, but momentum indicators suggest the rally could have more room to run.

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap in a single day. "We think the market ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly LLY revealed 30 unusual trades. Delving into the details, we found 50% of traders ...

Big move on Thursday as investors in Eli Lilly and Company (LLY) endured an almost 12% downside as investors consider the aftermath of the CVS formulary decision changes that impacted the ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...

Eli Lilly (NYSE: NYSE:LLY) is set to report its first-quarter earnings on Thursday, May 1st, before the market opens. Analysts expect the drugmaker to earn $3.46 (+34.1% Y/Y) on revenue of $12.72B ...

David Ricks; Chairman of the Board, President, Chief Executive Officer; Eli Lilly and Co Lucas Montarce; Executive Vice President and Chief Financial Officer; Eli Lilly and Co Daniel Skovronsky; ...

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...